The implantable sleep apnoea device developer raised $58.5m in a Zoll Medical-led round that took its total funding past the $140m mark.
Respicardia, the US-based developer of an implantable sleep apnoea treatment device, closed a $58.5m funding round on Monday led by medical device manufacturer Zoll Medical that included all its existing investors.
Originally known as Cardiac Concepts, Respicardia develops implantable therapies to treat respiratory and cardiovascular conditions.
The company’s first product, Remede System, is an implantable neurostimulation device that restores normal breathing patterns during sleep for sleep apnoea sufferers.
Remede received regulatory approval in the US in October this year, and…
